Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 1/20 | 0.47 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 3/20 | 0.44 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | MYC | P01106 | 1/20 | 0.43 |
| ▸ | MAX | P61244 | 1/20 | 0.43 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16799699 | 1.00 | PDE5A (0.47) | PDE5AGPR139NPSR1HDAC1HDAC2 | |
| SCHEMBL17680606 | 0.85 | NPSR1 (0.59) | NPSR1HDAC1HDAC2GRM5HPGD | |
| SCHEMBL4173714 | 0.83 | ATM (0.58) | GPR139NPSR1NPC1RAB9ATAS1R3 | |
| SCHEMBL7399516 | 0.82 | HPGD (0.66) | GPR139HPGDNPC1RAB9A | |
| SCHEMBL27564835 | 0.82 | GPR139 (0.66) | GPR139NPSR1NPC1RAB9ATAS1R3 | |
| SCHEMBL4176124 | 0.82 | GPR139 (0.66) | GPR139NPSR1NPC1RAB9ATAS1R3 | |
| SCHEMBL31530474 | 0.82 | KDM4C (0.48) | PDE5AGPR139NPSR1HPGDNPC1 | |
| SCHEMBL9943346 | 0.80 | GAA (0.58) | GPR139HPGDNPC1RAB9A | |
| SCHEMBL1686722 | 0.80 | GAA (0.58) | GPR139HPGDNPC1RAB9A | |
| SCHEMBL31530476 | 0.78 | SETD7 (0.58) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3077369-B1 | BENZAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERS AND PAIN AND FOR CONTROLLING SPASTICITY AND TREMORS | UCL BUSINESS PLC (GB) | 2019-03-13 | — | — | EP | disclosed |
| EP-3077369-B1 | BENZAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERS AND PAIN AND FOR CONTROLLING SPASTICITY AND TREMORS | UCL BUSINESS PLC (GB) | 2019-03-13 | — | — | EP | disclosed |
| US-20180116983-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | CANBEX THERAPEUTICS LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| US-20180116983-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | CANBEX THERAPEUTICS LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| US-20180116983-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | CANBEX THERAPEUTICS LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| US-9908843-B2 | Benzamide derivatives useful in the treatment of muscular disorders and pain and for controlling spasticity and tremors | CANBEX THERAPEUTICS LIMITED (GB) | 2018-03-06 | — | — | US | disclosed |
| US-9908843-B2 | Benzamide derivatives useful in the treatment of muscular disorders and pain and for controlling spasticity and tremors | CANBEX THERAPEUTICS LIMITED (GB) | 2018-03-06 | — | — | US | disclosed |
| US-9908843-B2 | Benzamide derivatives useful in the treatment of muscular disorders and pain and for controlling spasticity and tremors | CANBEX THERAPEUTICS LIMITED (GB) | 2018-03-06 | — | — | US | disclosed |
| EP-3256112-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | Canbex Therapeutics Limited (GB) | 2017-12-20 | — | — | EP | disclosed |
| US-20160304441-A1 | BENZAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERS AND PAIN AND FOR CONTROLLING SPASTICITY AND TREMORS | UCL BUSINESS PLC (GB) | 2016-10-20 | — | — | US | disclosed |
| US-20160304441-A1 | BENZAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERS AND PAIN AND FOR CONTROLLING SPASTICITY AND TREMORS | UCL BUSINESS PLC (GB) | 2016-10-20 | — | — | US | disclosed |
| US-20160304441-A1 | BENZAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERS AND PAIN AND FOR CONTROLLING SPASTICITY AND TREMORS | UCL BUSINESS PLC (GB) | 2016-10-20 | — | — | US | disclosed |
| EP-3077369-A1 | BENZAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERSAND PAIN AND FOR CONTROLLING SPASTICITY AND TREMORS | Canbex Therapeutics Limited (GB) | 2016-10-12 | — | — | EP | disclosed |
| WO-2016128771-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | CANBEX THERAPEUTICS LIMITED (GB) | 2016-08-18 | — | — | WO | disclosed |
| WO-2016128771-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | CANBEX THERAPEUTICS LIMITED (GB) | 2016-08-18 | — | — | WO | disclosed |
| CN-105793237-A | Benzamide derivatives for the treatment of muscular disorders and pain and for the control of spasticity and tremors | 坎贝克斯治疗有限公司 | 2016-07-20 | — | — | CN | disclosed |
| WO-2015082938-A1 | BENZAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERSAND PAIN AND FOR CONTROLLING SPASTICITY AND TREMORS | CANBEX THERAPEUTICS LIMITED (GB) | 2015-06-11 | — | — | WO | disclosed |
| WO-2015082938-A1 | BENZAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERSAND PAIN AND FOR CONTROLLING SPASTICITY AND TREMORS | CANBEX THERAPEUTICS LIMITED (GB) | 2015-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180116983-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | HCN4, KCNJ4, KCNQ4 | PDE5A 1773/4885GPR139 361/4885NPSR1 263/4885 |
| US-20160304441-A1 | BENZAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERS AND PAIN AND FOR CONTROLLING SPASTICITY AND TREMORS | MUSK, MYLK2, CBR3 | PDE5A 2504/4885GPR139 370/4885NPSR1 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.